X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (852) 852
index medicus (641) 641
oncology (556) 556
male (519) 519
hematology (518) 518
female (505) 505
middle aged (465) 465
aged (412) 412
rituximab (409) 409
adult (385) 385
indolent lymphoma (378) 378
indolent (363) 363
non-hodgkins-lymphoma (321) 321
follicular lymphoma (287) 287
antineoplastic combined chemotherapy protocols - therapeutic use (243) 243
treatment outcome (240) 240
chemotherapy (230) 230
lymphomas (221) 221
aged, 80 and over (194) 194
chronic lymphocytic-leukemia (172) 172
cancer (168) 168
therapy (166) 166
prognosis (156) 156
lymphoma (151) 151
lymphoma, follicular - drug therapy (143) 143
disease-free survival (136) 136
care and treatment (132) 132
trial (130) 130
1st-line treatment (128) 128
antineoplastic agents - therapeutic use (128) 128
b-cell lymphoma (126) 126
bendamustine (126) 126
lymphoma, non-hodgkin - drug therapy (121) 121
plus rituximab (121) 121
survival (115) 115
mantle cell lymphoma (114) 114
retrospective studies (114) 114
anti-cd20 monoclonal-antibody (113) 113
antibodies, monoclonal, murine-derived (110) 110
fludarabine (105) 105
low-grade (104) 104
phase-ii (103) 103
recurrence (100) 100
antibodies, monoclonal - therapeutic use (97) 97
medicine & public health (97) 97
cyclophosphamide (94) 94
antineoplastic combined chemotherapy protocols - adverse effects (92) 92
neoplasm staging (92) 92
multicenter (91) 91
survival analysis (89) 89
immunotherapy (87) 87
analysis (86) 86
antineoplastic combined chemotherapy protocols - administration & dosage (86) 86
non-hodgkin-lymphoma (85) 85
transplantation (85) 85
non-hodgkin's lymphomas (83) 83
lymphoma, follicular - pathology (82) 82
follow-up studies (81) 81
open-label (78) 78
remission induction (77) 77
animals (76) 76
diagnosis (76) 76
combined modality therapy (75) 75
high-dose therapy (75) 75
lymphoma, mantle-cell - drug therapy (75) 75
survival rate (75) 75
young adult (74) 74
vidarabine - analogs & derivatives (73) 73
hemic and lymphatic diseases (72) 72
pathology (72) 72
bendamustine hydrochloride (71) 71
cyclophosphamide - administration & dosage (71) 71
immunology (71) 71
research (71) 71
leukemia (69) 69
lymphoma, follicular - mortality (69) 69
hematology, oncology and palliative medicine (68) 68
lymphoma, b-cell - drug therapy (68) 68
term-follow-up (68) 68
indolent b-cell (67) 67
indolent systemic mastocytosis (67) 67
patients (66) 66
antineoplastic agents (65) 65
lymphoma, follicular - therapy (65) 65
non-hodgkin lymphoma (65) 65
phase-ii trial (65) 65
risk factors (65) 65
low-grade lymphoma (64) 64
antimitotic agents (62) 62
classification (61) 61
stem-cell transplantation (61) 61
abridged index medicus (60) 60
antibodies, monoclonal, murine-derived - administration & dosage (60) 60
disease progression (60) 60
progression-free survival (60) 60
combination (58) 58
leukemia, lymphocytic, chronic, b-cell - drug therapy (58) 58
bone-marrow-transplantation (57) 57
indolent lymphomas (56) 56
antibodies, monoclonal - administration & dosage (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1272) 1272
French (42) 42
German (23) 23
Russian (5) 5
Spanish (5) 5
Polish (3) 3
Korean (2) 2
Portuguese (2) 2
Turkish (2) 2
Czech (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2015, Volume 13, Issue 5.5, pp. 666 - 669
As targeted therapy in B-cell lymphomas rapidly expands beyond anti-CD20 monoclonal antibodies, many newer types of agents are in various stages of... 
ONCOLOGY | INDOLENT LYMPHOMA | LENALIDOMIDE
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 02/2015, Volume 21, Issue 2, pp. 281 - 287
Relapse is least common in patients with indolent B cell (iB) malignancies (ie, iB non-Hodgkin lymphoma [NHL]) who undergo nonmyeloablative allogeneic... 
Indolent lymphoma | Radioimmunotherapy | Nonmyeloablative transplantation
Journal Article
BLOOD, ISSN 0006-4971, 08/2019, Volume 134, Issue 9, pp. 761 - 764
Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known about the risk of... 
HEMATOLOGY | 1ST-LINE TREATMENT | INDOLENT
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2019, Volume 37, Issue 9, pp. 758 - 758
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2010, Volume 66, Issue 3, pp. 413 - 423
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 26, pp. 3272 - 3278
Purpose This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series... 
SURVIVAL | DIAGNOSIS | ONCOLOGY | REFRACTORY LOW-GRADE | HIGH-DOSE THERAPY | RITUXIMAB | NON-HODGKINS-LYMPHOMA | I-131 TOSITUMOMAB | INDOLENT | HISTOLOGICAL TRANSFORMATION | CHEMOTHERAPY | ORIGINAL REPORTS | Hema10
Journal Article
Journal Article
Current Oncology, ISSN 1198-0052, 2017, Volume 24, Issue 4, pp. 262 - 270
The 2017 annual meeting of the American Society of Clinical Oncology took place in Chicago, Illinois, 2-6 June. At the meeting, results from key studies in the... 
First-line treatment | Indolent non-hodgkin lymphoma | Untreated | Front-line treatment | TRIAL | 1ST-LINE TREATMENT | MANTLE-CELL | MULTICENTER | ONCOLOGY | Indolent non-Hodgkin lymphoma, untreated | BENDAMUSTINE PLUS RITUXIMAB | front-line treatment | CHOP | first-line treatment | CVP | INDOLENT | Meeting Report
Journal Article
Cancer discovery, ISSN 2159-8274, 10/2018, Volume 8, Issue 10, pp. 1258 - 1269
This multicenter phase 1/2 clinical trial evaluated intratumoral SD-101, a TLR9 agonist, and low-dose radiation in patients with untreated indolent lymphoma.... 
In Situ Vaccine | Clinical Trial | Indolent Lymphoma | CpG
Journal Article
Annales de Pathologie, ISSN 0242-6498, 02/2019, Volume 39, Issue 1, pp. 29 - 35
Herein we report the case of a 41-year-old woman who presented with pelvic pain. Magnetic Resonance Imaging exhibited a single pelvic mass, measuring 50 mm... 
Localized Castleman disease | Indolent T-lymphoblastic proliferation
Journal Article
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, ISSN 2212-5558, 10/2019
Journal Article
Journal Article
Annales de Dermatologie et de Venereologie, ISSN 0151-9638, 12/2012, Volume 139, Issue 12, pp. 812 - 817
Background: Indolent non-epidermotropic CD8+ lymphoid proliferation of the ear was recently reported in the literature by Petrella et al. This is a distinct... 
CD8 | Indolent | Cutaneous lymphoma
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S109 - S111
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 05/2018, Volume 11, Issue 5, pp. 403 - 410
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.